GlassScriptPhysician profile
Jonathan Lawrence Abbott
NPI 1730455775
$17,649.51
in general payments reported to CMS, 2019-2025
27 companies · $3,976 in 2025
The $3,976 reported for 2025 was more than what 96% of Obstetrics & Gynecology providers received nationally (typical 2025 total: $158).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $30.39 · 2020: $187 · 2021: $421 · 2022: $489 · 2023: $208 · 2024: $12K · 2025: $3,976.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $12K · Consulting Fee: $2,184 · Food and Beverage: $1,667 · Travel and Lodging: $190.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $12,480.00 |
| Consulting Fee | $2,184.00 |
| Food and Beverage | $1,667.27 |
| Travel and Lodging | $190.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Biogen, INC. | $15,593.62 | 2024-2025 | Zurzuvae |
| Abbvie INC. | $369.75 | 2020-2022 | |
| Aspira Women'S Health INC | $349.53 | 2022-2024 | Ova1 |
| Exeltis, USA INC. | $164.33 | 2021-2025 | Slynd |
| Pfizer INC. | $155.49 | 2021-2024 | |
| Organon LLC | $146.00 | 2021-2024 | Nexplanon |
| Therapeuticsmd, INC. | $93.39 | 2021-2022 | |
| Sumitomo Pharma America, INC. | $84.58 | 2023-2024 | Myfembree |
| Hologic Sales and Service, LLC | $73.09 | 2020-2025 | Sonata Sonography-Guided Transcervical Fibroid Ablation System |
| Millicent US INC | $65.96 | 2022-2023 | Femring, Intrarosa |
| Ethicon US, LLC | $56.94 | 2021-2024 | Enseal X1 |
| Myovant Sciences INC. | $54.52 | 2021-2022 | |
| Merck Sharp & Dohme LLC | $44.00 | 2020 | |
| Shield Therapeutics INC | $43.41 | 2023-2024 | Accrufer |
| Sage Therapeutics, LLC | $40.46 | 2021-2022 |
Show all 27 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Agile Therapeutics, INC. | $37.53 | 2021-2022 | |
| Amgen INC. | $34.96 | 2021-2025 | Prolia, Evenity |
| Medtronic, INC. | $30.45 | 2024 | Truclear |
| Ferring Pharmaceuticals INC. | $30.39 | 2019 | |
| Bayer Healthcare Pharmaceuticals INC. | $28.07 | 2021-2022 | |
| Baxter Healthcare | $27.96 | 2024 | Perclot |
| Innovation Technologies INC | $24.99 | 2025 | Irrisept |
| Avanos Medical | $22.76 | 2023 | On-Q* Pump and Accessories |
| Exact Sciences Corporation | $22.33 | 2024 | Cologuard Collection Kit |
| Daiichi Sankyo INC. | $21.94 | 2020 | |
| Gynesonics, INC. | $17.65 | 2025 | Sonata Sonography-Guided Transcervical Fibroid Ablation System |
| Olympus America INC. | $15.41 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jonathan Abbott listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.